Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA

Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.

RTTNews | Před 548 dny

Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia

Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia disorders.

RTTNews | Před 688 dny

Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease

Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with ENTYVIO intravenous (IV).

RTTNews | Před 700 dny

Takeda Reports Positive Topline Results Of Phase 2b Study Of TAK-279 For Active Psoriatic Arthritis

Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) announced Monday positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis.

RTTNews | Před 702 dny

Additional Support Anticipated For South Korea Shares

EURUSD	1.1709	GBPUSD	1.35808	AUDUSD	0.65468
USDJPY	147.229	USDCAD	1.37533	USDCHF	0.80514

Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA

Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia

Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease

Takeda Reports Positive Topline Results Of Phase 2b Study Of TAK-279 For Active Psoriatic Arthritis

Additional Support Anticipated For South Korea Shares

South Korea Export Prices Climb 1.0% In July

Australia Unemployment Data Due On Thursday

Swiss Franc Retreats Against Majors